Early results show promise of CAR-T cell therapy for treating rare blood cancer
Eight of 11 patients (72.7%) treated in a early stage international clinical trial of a new drug for a rare form of blood cancer achieved complete remission, meaning there were no signs of cancer after treatment, a new study shows.
